Berberine (BBR), an isoquinoline derivative alkaloid, has been extensively used in traditional Chinese medicine for the treatment of diarrhoea, rheumatic diseases, diabetes, etc. Recent studies have demonstrated new biological properties of BBR and suggested the possibility of BBR to be a therapeutic agent for some autoimmune diseases. To explore the effect of BBR on the development of experimental autoimmune neuritis (EAN), BBR was administered intragastrically daily to Lewis rats immunized with P0 peptide 180-199 in Freund's complete adjuvant. We found BBR treatment resulted in amelioration of EAN, accompanied by suppressed lymphocyte (in particular CD4 + T cell) proliferation, downregulated Th1 (TNF-a) and Th2 (IL-10) cytokines and reduced anti-P0 peptide 180-199 IgG1 and IgG2a. In brief, BBR played a role in ameliorating EAN by suppressing both cellular and humoral immunity. Thus, our study suggests that BBR may be a potential therapeutic agent for the autoimmune disease in the peripheral nervous system, such as Guillain-Barr e syndrome.
Human brucellosis is a re-emerging bacterial anthropozoonotic disease, which remains a public health concern in China with the growing number of cases and more widespread natural foci. The purpose of this study was to short-term forecast the incidence of human brucellosis with a prediction model. We collected the annual and monthly laboratory data of confirmed cases from January 2004 to December 2013 in Shandong Diseases Reporting Information System (SDRIS). Autoregressive integrated moving average (ARIMA) model was fitted based on the monthly human brucellosis incidence from 2004 to 2013. Finally, monthly brucellosis incidences in 2014 were short-term forecasted by the obtained model. The incidence of brucellosis was increasing from 2004 to 2013. For the ARIMA (0, 2, 1) model, the white noise diagnostic check (x(2) = 5.58 P = 0.35) for residuals obtained was revealed by the optimum goodness-of-fit test. The monthly incidences that fitted by ARIMA (0, 2, 1) model were closely consistent with the real incidence from 2004 to 2013. And forecasting incidences from January 2014 to December 2014 were, respectively, 0.101, 0.118, 0.143, 0.166, 0.160, 0.172, 0.169, 0.133, 0.122, 0.105, 0.103 and 0.079 per100 000 population, with standard error 0.011-0.019 and mean absolute percentage error (MAPE) of 58.79%.
Our results suggest that high Sam68 expression predicts poor prognosis of NSCLC patients, and Sam68 may be potentially a prognostic biomarker for NSCLC.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.